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Background
Polymers containing immunogenic peptides bonded to
dendrimeric structures have been developed to be used
for vaccines in cancer, infectious diseases, and allergy.
Our aim is to design a dendrimeric structure containing
Ole e 1 and CpG, in order to modulate an allergic
immune response towards Th1, in an experimental
model of anaphylaxis.
Methods
C56BL/6 mice were sensitized by intranasal administration
of olive extract+cholera toxin B, for 6 weeks. Then, mice
received immunotherapy (IT) treatment by subcutaneous
(sc) injection of dendrimer-Ole1±50 mg of CpG, for
8 weeks. Seven days after the IT, mice were challenged
with 100 mg of olive extract (ip). Severity of anaphylaxis
was measured by drop in body temperature and the
humoral response by ELISA.
Results
Olive sensitized mice treated with the dendrimer-Ole1
without CpG developed a drop in body temperature simi-
lar to anaphylactic mice (35.02±1.39 vs 34.48±0.82,
respectively), indicating that Ole e 1 within a dendrimeric
structure is recognized in vivo. On the other hand,
8 weeks after immunotherapy, mice receiving the dendri-
mer-Ole1+CpG were significantly protected from the
development of systemic anaphylaxis (37.18±1.58 vs
34.48±0.82, p‹0.05, respectively). IgE and IgG2a levels
decreased after 1-2 weeks of treatment and remained
stable over the time; however IgG1 levels were normal.
Conclusion
Our results indicate that the dendrimer-Ole1 is recognized
in vivo. Furthermore, we show that sc administration of
dendrimer-Ole1+CpG protects sensitized mice from the
onset of anaphylaxis, and the decrease in IgE levels during




1Research Laboratory, IMABIS Foundation-Carlos Haya Hospital/Bionand,
Malaga, Spain. 2Glycosystems Laboratory, Instituto de Investigaciones
Químicas, CSIC, Seville, Spain. 3Allergy Service, Carlos Haya Hospital, Malaga,
Spain.
Published: 25 July 2013
doi:10.1186/2045-7022-3-S3-P81
Cite this article as: Blazquez et al.: Design of dendrimeric structures to
treat allergic disorders. Clinical and Translational Allergy 2013 3(Suppl 3):
P81.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
1Research Laboratory, IMABIS Foundation-Carlos Haya Hospital/Bionand,
Malaga, Spain
Full list of author information is available at the end of the article
Blazquez et al. Clinical and Translational Allergy 2013, 3(Suppl 3):P81
http://www.ctajournal.com/content/3/S3/P81
© 2013 Blazquez et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
